Rapport Therapeutics, Inc.

• Cash Runway : The Company expects that cash, cash equivalents, and short-term investments as of June 30, 2025 will enable the Company to fund its operating expenses and capital expenditure requirements through the end of 2026.

SEC original ↗Rapport Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

The Company expects that its cash, cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these condensed consolidated financial statements.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through equity offerings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

10 Short-Term Investments The Company s short-term investments consist of investments in debt securities, including U.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

As of June 30, 2026 and December 31, 2025, all of the Company s debt securities were classified as available-for-sale and were carried at fair market value (see Note 3).

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The unrealized gains and losses on the Company s available-for-sale debt securities are recorded in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Our team remains focused on executing these critical milestones and continuing to invest in our promising precision neuroscience discovery programs.

SEC original ↗Rapport Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Due to the significant resources required for the development of our pipeline, and depending on our ability to access capital, we must prioritize the development of certain product candidates over others.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

The Company will need additional financing to support its continuing operations and pursue its growth strategy.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through equity offerings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Rapport’s business, operating results, financial condition and stock value.

SEC original ↗Rapport Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Rapport’s intellectual property protections; and risks related to the competitive landscape for Rapport’s product candidates; as well as other risks described in “Risk Factors,” in the Company’s Annual Report on Form 10-K, and most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Rapport’s subsequent filings with the Securities and Exchange Commission.

SEC original ↗Rapport Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Rapport’s business, operating results, financial condition and stock value.

SEC original ↗Rapport Therapeutics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025

Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Rapport’s intellectual property protections; and risks related to the competitive landscape for Rapport’s product candidates; as well as other risks described in​ “Risk Factors,” in the company’s Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Rapport’s subsequent filings with the Securities and Exchange Commission.

SEC original ↗Rapport Therapeutics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025

Legal Proceedings 41 Item 1A.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Rapport Therapeutics, Inc. — 10-Q Quarterly report10-QAug 5, 2026